TRI NEXOVAS 40 MG TAB

1. All Details: Specifications
Active Pharmaceutical Ingredients: Cilnidipine IP, Olmesartan Medoxomil IP, and Chlorthalidone IP.
Dosage Form: Film-coated tablet.
Coloring Agents: Titanium Dioxide IP.
Storage Environment: Store in a cool and dry place.
Regulatory Classification: SCHEDULE G PRESCRIPTION DRUG – CAUTION: It is dangerous to take this preparation except under medical supervision.
Special Clinical Warning: WARNING: When pregnancy is detected, Olmesartan should be discontinued as soon as possible as it can cause injury and even death to the developing fetus when used during second and third trimester of pregnancy.
Manufacturing License Number (Mfg. Lic. No.): M/681/2015.
Internal Material Reference: PM03282601.
2. General Information
Brand: TriNexovas™ 40 (printed as TriNexovas™ 40).
Name: Cilnidipine, Olmesartan Medoxomil and Chlorthalidone Tablets.
Quantity: Typically distributed in standard silver aluminum blister configurations (such as strips of 10 or 15 tablets); precise count text is segmented on the primary foil.
Type: Prescription Triple-Combination Antihypertensive Cardiovascular Medication.
Factor (Form Factor): Solid oral tablet (Film-coated).
Maximum Shelf Life: Standard pharmaceutical shelf life for this multi-action oral layout is usually 24 months from the production date (refer to the stamped edge matrix on your physical pack for your exact batch timeline).
Food Preference: Not Applicable. As a critical prescription cardiovascular chemical compound, standard consumer dietary classification symbols (like vegetarian green dots) are absent.
FSSAI: Not Applicable. This high-potency prescription drug is strictly controlled under the Drugs and Cosmetics Act by the CDSCO. It is not a dietary health supplement, so it does not fall under the jurisdiction of the FSSAI (Food Safety and Standards Authority of India).
3. Product Details: Ingredients
Each film-coated tablet contains:
Cilnidipine IP: 10 mg
Olmesartan Medoxomil IP: 40 mg
Chlorthalidone IP: 12.5 mg
Excipients: Details are listed under primary formulary specifications.
4. Directions: How to Use
Dosage: As directed by the Physician.
Administration Instructions: The tablet must be swallowed whole with a glass of water, usually taken at the same time every single day to maximize therapeutic control. It can be taken with or without food. Do not chew, break, or crush the tablet before swallowing, as doing so may disrupt the intentional distribution rate of the individual film-coated active ingredients.

5. Description
Tri Nexovas 40 is a potent, triple-combination prescription medication designed for the comprehensive management of systemic hypertension (high blood pressure) when single or dual-agent therapies are insufficient. It strategically merges three distinct therapeutic pathways to achieve optimal blood pressure management: Cilnidipine (a dual L/N-type calcium channel blocker that relaxes vascular smooth muscle and attenuates sympathetic nerve activity), Olmesartan Medoxomil (an angiotensin II receptor antagonist that inhibits systemic vasoconstriction), and Chlorthalidone (a long-acting thiazide-like diuretic that promotes fluid and sodium elimination from the bloodstream). The packaging contains an highly crucial black box safety warning warning female patients to immediately stop use if pregnancy occurs due to fetal toxic risks associated with Olmesartan. It also incorporates a Schedule G prescription label indicating it must only be taken under direct medical supervision.
6. Manufacturer Information
Manufactured in India by: MACLEODS PHARMACEUTICALS LTD.
Plant Address: Khasra No. 21, 22, 66, 67 & 68, Aho-Yangtam, Namchepung, PO: Ranipool, Sikkim – 737135.
7. Marketed By
Marketed by: MACLEODS PHARMACEUTICALS LTD.